Gilead signs deals with Indian companies for low-cost HIV drug

Thu Aug 2, 2012 7:19pm IST

Related Topics

Stocks

   

(Reuters) - Gilead Sciences Inc signed deals with three Indian companies to drive sales and reduce manufacturing costs of low-cost generic versions of its HIV drug emtricitabine in developing countries.

Under deals with Ranbaxy Laboratories, Strides Arcolab and Mylan Inc's India unit, Gilead will provide technology and funding to help reduce manufacturing costs of the drug, the companies said.

Gilead, which sells the drug under the Emtriva brand, is the world's largest maker of branded drugs to treat the human immunodeficiency virus -- the cause of AIDS.

(Reporting by Shailesh Kuber; Editing by Viraj Nair)

FILED UNDER:

REUTERS EXCLUSIVE

Reuters Showcase

World Cup 2015

World Cup 2015

Dhoni, bowlers shine as India book quarter-final place.  Full Article 

Reuters Poll

Reuters Poll

Rupee to depreciate marginally, yuan to rise a little.  Full Article 

Rape Accused Killed

Rape Accused Killed

Mob in Nagaland breaks into jail, lynches rape suspect.  Full Article 

Govt vs RBI

Govt vs RBI

Government faces potential clashes with RBI over who decides rates.  Full Article 

'India's Daughter'

'India's Daughter'

Society created Delhi gang rape convicts: Filmmaker Leslee Udwin.  Full Article | Related Story 

Ford Injured

Ford Injured

Actor Harrison Ford injured in small-plane crash in Los Angeles.  Full Article 

China Attack

China Attack

Knife attack wounds 9 at Chinese train station, suspect shot dead.  Full Article 

Holi Hai!

Holi Hai!

In Pictures: Festival of Colours.  Full Coverage 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device  Full Coverage